Earnings History Data for Supernus Pharmaceuticals, Inc. (SUPN) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 04-11-2024 | AH | SUPN | Supernus Pharmaceuticals, Inc. | 1,880 | 0.95 | 0.27 | -0.29 | Supernus Pharmaceuticals GAAP EPS of $0.69, revenue of $175.69M beats by $18.39M [11/4/2024 4:15 PM] |
34.79 | 0.09 (0.26%) |
37.00 | 2.30 (6.63%) |
23.05 - 39.37 | 808,152 | 330,000 | 22,437 | ||
| 06-08-2024 | AH | SUPN | Supernus Pharmaceuticals, Inc. | 1,630 | 0.36 | 0.25 | -0.02 | Supernus Pharmaceuticals beats top-line and bottom-line estimates; raises FY24 outlook [8/6/2024 4:47 PM] |
31.63 | 3.75 (13.45%) |
27.88 | 0.0 (0.00%) |
21.99 - 35.44 | 1,604,935 | 470,000 | 11,460 | ||
| 08-05-2024 | AH | SUPN | Supernus Pharmaceuticals, Inc. | 1,670 | N/A | 0.27 | 0.29 | Supernus Pharmaceuticals reports mixed Q1 results; reaffirms FY24 outlook [5/8/2024 4:56 PM] |
29.94 | -1.36 (-4.35%) |
31.30 | 0.0 (0.00%) |
21.99 - 38.08 | 952,981 | 370,000 | 17,385 | ||
| 27-02-2024 | AH | SUPN | Supernus Pharmaceuticals, Inc. | 1,590 | 0.02 | 0.41 | 0.43 | Supernus Pharmaceuticals GAAP EPS of $0.02 beats by $0.04, revenue of $164.3M beats by $9.27M [2/27/2024 4:28 PM] |
31.12 | 0.43 (1.41%) |
28.23 | -2.46 (-8.02%) |
21.99 - 40.12 | 830,199 | 370,000 | 13,139 | ||
| 08-11-2023 | AH | SUPN | Supernus Pharmaceuticals, Inc. | 1,310 | -0.29 | 0.13 | 0.03 | Supernus Pharmaceuticals GAAP EPS of -$0.29 in-line, revenue of $153.88M beats by $10.49M [11/8/2023 4:39 PM] |
26.15 | 2.63 (11.18%) |
24.75 | 1.23 (5.23%) |
21.99 - 42.09 | 910,341 | 450,000 | 1,540 | ||
| 08-08-2023 | AH | SUPN | Supernus Pharmaceuticals, Inc. | 1,750 | -0.02 | 0.23 | 0.14 | Supernus Pharmaceuticals GAAP EPS of -$0.02 beats by $0.21, revenue of $135.6M misses by $8.06M [8/8/2023 4:33 PM] |
30.31 | -2.60 (-7.90%) |
31.45 | -1.46 (-4.44%) |
29.06 - 42.09 | 1,275,832 | 390,000 | 6,138 | ||
| 09-05-2023 | AH | 4:05 PM ET (May 9) |
SUPN | Supernus Pharmaceuticals, Inc. | 2,000 | 0.29 | 0.12 | 0.43 | Supernus Pharmaceuticals GAAP EPS of $0.29 beats by $0.55, revenue of $153.8M beats by $14.78M [5/9/2023 4:20 PM] |
36.65 | 0.47 (1.30%) |
36.18 | 0.0 (0.00%) |
24.95 - 42.09 | 683,013 | 260,000 | 3,999 | |
| 28-02-2023 | AH | 4:05 PM ET (Feb 28) |
SUPN | Supernus Pharmaceuticals, Inc. | 2,090 | 0.43 | 0.73 | 0.04 | Supernus Pharmaceuticals reports Q4 results, sees FY 2023 revenue in-line [2/28/2023 4:27 PM] |
39.19 | 1.60 (4.26%) |
37.59 | 0.0 (0.00%) |
24.95 - 42.09 | 713,493 | 340,000 | 12,936 | |
| 08-11-2022 | AH | 4:00 PM ET (Nov 8) |
SUPN | Supernus Pharmaceuticals, Inc. | 1,840 | 0.03 | 0.31 | 0.40 | Supernus Pharmaceuticals GAAP EPS of $0.03 misses by $0.33, revenue of $177.35M beats by $4.87M [11/8/2022 4:20 PM] |
32.80 | -1.90 (-5.48%) |
34.70 | 0.0 (0.00%) |
24.95 - 36.08 | 616,131 | 350,000 | 49,742 | |
| 04-08-2022 | AH | 4:05 PM ET (Aug 4) |
SUPN | Supernus Pharmaceuticals, Inc. | 1,630 | 0.14 | 0.29 | 0.43 | Supernus Pharmaceuticals GAAP EPS of $0.14 misses by $0.15, revenue of $170.05M beats by $5.82M [8/4/2022 4:08 PM] |
32.16 | -0.65 (-1.98%) |
32.16 | 0.0 (0.00%) |
23.15 - 34.50 | 640,765 | 410,000 | 4,310 | |
| 09-05-2022 | AH | 4:10 PM ET (May 9) |
SUPN | Supernus Pharmaceuticals, Inc. | 1,500 | 0.43 | 0.26 | 0.11 | Supernus Pharmaceuticals GAAP EPS of $0.43 misses by $0.02, revenue of $152.51M beats by $2.04M [5/9/2022 4:15 PM] |
26.01 | -0.36 (-1.35%) |
26.37 | 0.0 (0.00%) |
23.15 - 34.50 | 551,233 | 479,953 | 9,302 | |
| 13-04-2022 | AH | 4:00 PM ET (Apr 4) |
SUPN | Supernus Pharmaceuticals | 1,683 | 0.04 | 0.24 | 0.00 | Supernus Pharmaceuticals GAAP EPS of $0.04 misses by $0.20, revenue of $159.05M in-line [4/13/2022 4:16 PM] |
31.11 | -1.52 (-4.66%) |
31.75 | -0.88 (-2.70%) |
23.15 - 34.50 | 412,827 | 530,000 | 734 | |
| 28-02-2022 | AH | 4:00 PM ET (Feb 28) |
SUPN | Supernus Pharmaceuticals, Inc. | 1,710 | N/A | 0.21 | 0.57 | Supernus Pharmaceuticals reports Q4 results [2/28/2022 4:17 PM] |
29.68 | -2.27 (-7.10%) |
29.50 | -2.45 (-7.67%) |
23.15 - 34.50 | 2,015,700 | 590,000 | 5,358 | |
| 03-11-2021 | AH | 4:10 PM ET (Nov 3) |
SUPN | Supernus Pharmaceuticals, Inc. | 1,610 | 0.40 | 0.21 | 0.74 | Supernus Pharmaceuticals EPS beats by $0.17, beats on revenue; updates full year guidance [11/3/2021 4:05 PM] |
31.56 | 1.53 (5.09%) |
31.56 | 0.0 (0.00%) |
20.22 - 34.29 | 873,632 | 320,000 | 3,207 | |
|
||||||||||||||||||
| 04-08-2021 | AH | 4:00 PM ET (Aug 4) |
SUPN | Supernus Pharmaceuticals, Inc. | 1,400 | 0.43 | 0.17 | 0.65 | Supernus Pharmaceuticals EPS beats by $0.23, beats on revenue [8/4/2021 4:19 PM] |
26.55 | -0.63 (-2.32%) |
26.83 | -0.35 (-1.29%) |
17.20 - 34.29 | 385,219 | 340,000 | 150 | |
|
||||||||||||||||||
| 05-05-2021 | AH | 4:00 PM ET (May 5) |
SUPN | Supernus Pharmaceuticals, Inc. | 1,610 | 0.11 | 0.26 | 0.40 | Supernus Pharmaceuticals EPS misses by $0.11, beats on revenue; reaffirms guidance [5/5/2021 4:04 PM] |
29.29 | -1.20 (-3.94%) |
29.29 | 0.0 (0.00%) |
17.20 - 32.31 | 795,750 | 460,000 | 5,834 | |
|
||||||||||||||||||
| 03-11-2020 | AH | 6:05 PM ET (Nov 3) |
SUPN | Supernus Pharmaceuticals, Inc. | 966.91 | 0.74 | 0.27 | 0.54 | Supernus Pharmaceuticals EPS beats by $0.47, beats on revenue [11/3/2020 4:32 PM] |
22.48 | 4.32 (23.83%) |
21.35 | 3.20 (17.63%) |
13.12 - 29.36 | 1,910,194 | 381,304 | 26,833 | |
|
|
||||||||||||||||||
| 18-08-2020 | AH | 6:45 PM ET (Aug 18) |
SUPN | Supernus Pharmaceuticals, Inc. | 1,270 | 0.65 | 0.35 | 0.61 | Supernus Pharmaceuticals EPS beats by $0.16, misses on revenue [8/18/2020 4:58 PM] |
24.02 | -1.03 (-4.11%) |
25.10 | 0.05 (0.20%) |
13.12 - 29.81 | 419,888 | 486,429 | 2,373 | |
|
|
||||||||||||||||||
| 05-05-2020 | AH | 4:40 PM ET (May 5) |
SUPN | Supernus Pharmaceuticals, Inc. | 1,220 | 0.40 | 0.30 | 0.34 | Supernus Pharmaceuticals EPS beats by $0.13, beats on revenue [5/5/2020 7:53 PM] |
22.17 | 0.03 (0.14%) |
0.0 | 0.0 (0.00%) |
13.12 - 38.74 | 353,891 | 498,004 | 0 | |
|
|
||||||||||||||||||